跳至主要内容
临床试验/EUCTR2020-001598-66-FR
EUCTR2020-001598-66-FR进行中(未招募)1 期

Preliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1

Centre Hospitalier de Versailles0 个研究点目标入组 20 人开始时间: 2020年4月16日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •At least 18 years and less than 75 years old.
  • •Intensive care unit admission.
  • •Intubation and mechanical ventilation since less than 72h.
  • •Positive end-expiratory pressure = 5 cmH2O.
  • •Acute respiratory distress syndrome following Berlin definition.
  • •PaO2/FiO2 ratio < 150 mmHg during at least 3 hours despite PEP trial.
  • •Compliance of the respiratory system < 50 mL/cmH2O
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 10
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 10

排除标准

  • •Contraindication to prone position.
  • •Weight < 40 kgs
  • •Height below 140 cm or above 190 cm.
  • •Profuse bronchorrhea
  • •Other significant cause than ARDS to the respiratory failure
  • •History of pneumonectomy or pulmonary lobectomy
  • •Limitation of therapeutics.
  • •No arterial line in place.
  • •Impossible to give neuromuscular blockers (e.g. drug unavailable).
  • •Severe chronic respiratory failure with oxygen at home.
  • •Other severe acute or chronic liver failure
  • •Patient scheduled for extracorporeal membrane oxygenation.
  • •Known hypersensibility to Curosurf.

研究者

相似试验